GettyImages-182157308-correctedligtscreenWithchestxxray.jpg
CA2_5031_Genevieve de Manio Photogrpahy_Arsanis 2016.05.19.jpg
GettyImages-182157308-correctedligtscreenWithchestxxray.jpg

Addressing Critical Infectious Disease Threats with Targeted Monoclonal Antibody Immunotherapies


 

 

SCROLL DOWN

Addressing Critical Infectious Disease Threats with Targeted Monoclonal Antibody Immunotherapies


 

 

Our current monoclonal antibody programs address specific bacterial and viral pathogens. Our Phase 2 program, ASN100, selectively targets Staphylococcus aureus virulence rather than directly killing the bacteria, potentially allowing Arsanis to combat critical infections without contributing to antibiotic resistance or damaging the patient’s microbiome.


featured news


CA2_5031_Genevieve de Manio Photogrpahy_Arsanis 2016.05.19.jpg

for investors & partners


Arsanis is uniquely positioned to discover and develop novel monoclonal antibody immunotherapies to prevent and treat serious infectious diseases.



Download our Corporate Presentation

SCROLL DOWN

for investors & partners


Arsanis is uniquely positioned to discover and develop novel monoclonal antibody immunotherapies to prevent and treat serious infectious diseases.



Download our Corporate Presentation